NASDAQ: BNTC · Life Sciences · 7 alerts · CIK 1808898
Share price
$8.54Close, Nov 16
Market cap
$298M
Shares outstanding
34.88MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Benitec Biopharma Inc. filings on SEC EDGAR ↗
Benitec Biopharma reported a net loss of $12.9 million for the quarter ended September 30, 2026, compared to $9.0 million in the prior year period, primarily driven by a significant increase in research and development expenses for their BB-301 program. The company maintained a strong liquidity position with $176.4 million in cash and cash equivalents to fund ongoing clinical development.
Benitec Biopharma reported financial results for its first fiscal quarter ended September 30, 2026, and announced a change in its fiscal year-end from June 30 to December 31. The company highlighted a 100% responder rate in its ongoing Phase 1b/2a study of BB-301 for OPMD and confirmed it remains on track to begin a pivotal trial in mid-2027.
Term
Q1 2027
“The consistency and durability of the clinical benefit observed to date continues to strengthen our conviction in the potential of BB-301 to meaningfully alter the course of OPMD-related dysphagia.”
Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer
Benitec Biopharma announced positive interim Phase 1b/2a results for its gene therapy BB-301 in patients with Oculopharyngeal Muscular Dystrophy (OPMD). The data showed a 100% responder rate across both low and high dose cohorts, with the high dose group demonstrating greater relative improvements in throat emptying and swallowing capacity at the 3-month mark.